Related Experiment Video

Updated: May 13, 2026

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib

Ahrum Min1, Seock-Ah Im, Young-Kwang Yoon

  • 1Cancer Research Institute, Seoul National University, Seoul, Republic of Korea.

Molecular Cancer Therapeutics
|March 21, 2013
PubMed

Insights

RAD51C deficiency enhances cancer cell sensitivity to the PARP inhibitor olaparib. This suggests RAD51C deficiency can serve as a biomarker for predicting olaparib

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Poly (ADP-ribose) polymerase (PARP) inhibitors are targeted therapies for cancers with DNA repair defects.
  • RAD51C, a RAD51 paralog, plays a crucial role in DNA damage response.

Purpose of the Study:

  • To investigate the relationship between RAD51C expression and sensitivity to the PARP inhibitor olaparib.
  • To determine if RAD51C deficiency can be a predictive biomarker for olaparib efficacy.

Main Methods:

  • Microarray analysis to assess RAD51C expression levels in cancer cell lines.
  • Functional studies involving RAD51C restoration and silencing in cancer cells.
  • Xenograft models to evaluate tumor growth suppression by olaparib.

Main Results:

  • Cancer cell lines with low RAD51C expression showed increased sensitivity to olaparib.
  • RAD51C-deficient cells exhibited enhanced cell death via G2-M arrest and apoptosis.
  • Restoring RAD51C reduced olaparib sensitivity, while silencing it increased sensitivity.
  • Olaparib suppressed tumor growth in RAD51C-deficient xenograft models.

Conclusions:

  • RAD51C deficiency significantly increases cancer cell sensitivity to olaparib.
  • RAD51C deficiency is a potential predictive biomarker for olaparib treatment.
  • Epigenetic downregulation of RAD51C occurs in some cancers, including gastric cancer.

More Related Videos

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging06:44

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage10:44

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

Related Concept Videos

DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Restarting Stalled Replication Forks02:37

Restarting Stalled Replication Forks

DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart, a...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...